Add
CLSN to Portfolio
Set Alert
Email to a
Friend
| |||
|
|
Quotes & Info
|
| CLSN > SEC Filings for CLSN > Form 8-K on 31-Jan-2013 | All Recent SEC Filings |
31-Jan-2013
Results of Operations and Financial Condition, Other Events, Financial Statements an
Please see the disclosure set forth under "Item 8.01 Other Events," which is incorporated by reference into this Item 2.02.
On January 31, 2013, Celsion Corporation ("Celsion" or the "Company") issued a press release announcing top-line results from the Company's pivotal Phase III trial of ThermoDox® (the "HEAT Study") for the treatment of hepatocellular carcinoma ("HCC"), also known as primary liver cancer, and reporting certain financial results for the year ended December 31, 2012. A copy of the press release is being filed as Exhibit 99.1 to this report.
Celsion will host a conference call to discuss these results at 8:00 a.m. EST on January 31, 2013. The conference call will also be broadcast at http://www.celsion.com.
The press release contains forward-looking statements which involve certain risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Please refer to the cautionary note in the press release regarding these forward-looking statements.
(d) Exhibits.
Exhibit
No. Description
99.1 Press release titled "Celsion Announces Results of Phase III HEAT Study of ThermoDox® in Primary Liver Cancer" issued by Celsion Corporation on January 31, 2013.
|
|